Condition
Moderate-to-severe autoimmune dermatitis
Lya Patient Hub
Clinical Trials
Matched trials based on your condition, location, and therapy history
Your Eligibility Profile
Current Therapy
ImmunaFlex (klevotimab)
Location
San Francisco, CA
Matched Trials
LUMINA-3: Phase III Study of LYA-987 in Refractory Autoimmune Dermatitis
NCT-2025-44821 · Lya Biopharma
Phase IIIUCSF San Francisco, CA3.2 miles away8 visits · 52 weeksCompensation: $150/visit
Evaluating efficacy and safety of LYA-987 (monoclonal antibody) vs placebo in adults with refractory disease.
Eligibility: Adults 18–65, inadequate response to 1+ biologic, no current oral immunosuppressant
Contact: lumina3@ucsf-research.edu
CARDIO-ADVANCE: Biomarker Study in Chronic Inflammatory Cardiomyopathy
NCT-2025-38901 · Stanford Heart Institute
Phase IIStanford Medical Center, CA31 miles away5 visits · 24 weeksCompensation: $75/visit
Observational biomarker collection study in patients with chronic inflammatory cardiomyopathy.
Eligibility: Diagnosed CIC within last 36 months, stable cardiac function, no recent hospitalization
Contact: cardio.advance@stanford-research.edu
Resources
- ClinicalTrials.gov patient search tool
- Lya Biopharma clinical research team: 1-800-555-0192
- Patient advocate for trial navigation available on request